


RealRate

PHARMACEUTICAL 2022

Catalent Inc. Rank 63 of 475







RealRate

PHARMACEUTICAL 2022

Catalent Inc. Rank 63 of 475

The relative strengths and weaknesses of Catalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Catalent Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 288% points. The greatest weakness of Catalent Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 139% points.

The company's Economic Capital Ratio, given in the ranking table, is 103%, being 380% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	2,918,000
Cost of Goods Sold	2,646,000
Intangible Assets	3,336,000
Liabilities, Current	1,196,000
Liabilities, Non-Current	175,000
Other Assets	334,000
Other Compr. Net Income	69,000
Other Expenses	149,000
Other Liabilities	3,467,000
Other Net Income	69,000
Property and Equipment	2,524,000
Research and Development	0
Revenues	3,998,000
Selling, General and Administrative Expense	687,000

Output Variable	Value in 1000 USD
Assets	9,112,000
Liabilities	4,838,000
Expenses	3,482,000
Stockholders Equity	4,274,000
Net Income	585,000
Comprehensive Net Income	619,500
Economic Capital Ratio	103%

